公开(公告)号：US11976103B2

公开(公告)日：2024-05-07

申请号：US17065395

申请日：2020-10-07

Applicant: Amgen Inc.

Inventor： Eric Alan Butz ,  Christy Ann Thomson ,  Marc Alain Gavin ,  Ian Nevin Foltz ,  Dong Xia ,  Dina N. Alcorn ,  Randal Robert Ketchem ,  Ai Ching Lim ,  Kathy Manchulenko ,  Laura Sekirov ,  Kelly Ann Berry ,  Cyr Clovis Chua De Imus ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Li Li

IPC: A61K38/20 ,  A61P37/00 ,  C07K14/55 ,  C07K16/24

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61P37/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US11976102B2

公开(公告)日：2024-05-07

申请号：US17063566

申请日：2020-10-05

Applicant: Amgen Inc.

Inventor： Marc Alain Gavin ,  Gunasekaran Kannan ,  Li Li ,  Joshua Thomas Pearson ,  Margaret Karow

IPC: A61K38/00 ,  C07K14/55 ,  C07K16/00

CPC classification number: C07K14/55 ,  C07K16/00 ,  A61K38/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

公开(公告)号：US10851144B2

公开(公告)日：2020-12-01

申请号：US15565376

申请日：2016-05-04

Applicant: AMGEN INC.

Inventor： Eric Alan Butz ,  Christy Ann Thomson ,  Marc Alain Gavin ,  Ian Nevin Foltz ,  Dong Xia ,  Dina N. Alcorn ,  Ai Ching Lim ,  Randal Robert Ketchum ,  Kathy Manchulenko ,  Laura Sekirov ,  Kelly Ann Berry ,  Cyr Clovis Chua De Imus ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Li Li

IPC: C07K14/55 ,  A61P37/00 ,  A61K38/20 ,  C07K16/24

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.